Regenerative medicine

Peak Human Announces Launch of the Psychedelic Frontiers Virtual Summit

Friday, October 22, 2021 - 1:11am

Summit will bring together over 40 leading experts in the field of psychedelics

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - October 21, 2021) - Peak Human, an organization dedicated to helping people improve their lives using a proven blend of ancient knowledge and brand new technologies, is thrilled to announce the launching of Psychedelic Frontiers Virtual Summit.
  • Hoping to add to the growing conversation around psychedelic medicine, the Psychedelic Frontiers Virtual Summit will bring together over 40 leading experts shaping the role of psychedelics in our world.
  • We're excited to put on this free summit to help educate people and bring attention to this very important development in mental health."
  • It provides cutting edge health information and medical services globally to individuals who desire to be and stay in a "Peak" state.

Dr. Jason Schottel, PhD, ARNP-C, DC, MBA, ABAAHP, AAOPM, FAAMM, FISCG, FAAAMS is recognized by Continental Who's Who

Thursday, October 21, 2021 - 6:39pm

Dr. Schottel first attended Florida State College at Jacksonville, earning his Bachelor's degree in Business.

Key Points: 
  • Dr. Schottel first attended Florida State College at Jacksonville, earning his Bachelor's degree in Business.
  • Dr. Schottel received medical training at Saba University School of Medicine.
  • He was awarded his Ph.D. from Wilmington University and his Doctorate of Chiropractic from Palmer College of Chiropractic.
  • He then earned a BSN and MSN (ARNP) degree from South University, and received his MBA from Davenport University.

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

Thursday, October 21, 2021 - 2:30pm

and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors.

Key Points: 
  • and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors.
  • "It is with great pleasure that we welcome Rachelle to the uniQure board, stated Matthew Kapusta , chief executive officer of uniQure.
  • I am pleased with this opportunity to join the uniQure Board of Directors at such an exciting time for the Company, stated Ms. Jacques.
  • Since April 2019, Ms. Jacques has served on the Board of Directors of Corbus Pharmaceuticals (NASDAQ: CRBP), and from April 2020 to February 2021, she served on the Board of Directors of Viela Bio.

The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors

Thursday, October 21, 2021 - 2:00pm

Washington, DC, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2022 Officers, Executive Committee, and Board of Directors.

Key Points: 
  • Washington, DC, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2022 Officers, Executive Committee, and Board of Directors.
  • The Executive Committee and Board of Directors oversee the formation and execution of ARMs strategic priorities and focus areas for the coming year.
  • ARM welcomes the diverse expertise and experience of our 2022 Board of Directors, said ARM Chief Executive Officer Janet Lambert.
  • Group Vice President, Worldwide Research & Development Strategy, Scientific Collaborations and Policy, BioMarin
    Susan Nichols President & Chief Executive Officer, Propel BioSciences
    Karah Parschauer, J.D.

Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Thursday, October 21, 2021 - 1:30pm

EXTON, Pa., Oct. 21, 2021 /PRNewswire/ -- Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, today announced that the U.S. Food & Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the company a $1.825 million research grant over four years (#1R01–FD007289-01). The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

Key Points: 
  • The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
  • The Congressionally-funded Orphan Products Development Grants Program is designed to enhance the development of medical products for patients with rare diseases.
  • RDEB is a progressive, devastatingly painful and debilitating, rare genetic disorder, and one of the most chronic and severe forms of DEB.
  • Castle Creek Biosciences' dabocemagene autoficel (FCX-007, D-Fi) is being developed to address the deficiency of functional type VII collagen protein (COL7) in patients with dystrophic epidermolysis bullosa (DEB).

Generate Life Sciences Details Data Presented at the 2021 Annual ASRM and AABB Meetings

Thursday, October 21, 2021 - 1:00pm

LOS ANGELES, Oct. 21, 2021 /PRNewswire/ -- Generate Life Sciences recently presented data from its research programs during this year's American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo and the AABB (formerly known as the American Association of Blood Banks) Annual Meeting.

Key Points: 
  • LOS ANGELES, Oct. 21, 2021 /PRNewswire/ -- Generate Life Sciences recently presented data from its research programs during this year's American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo and the AABB (formerly known as the American Association of Blood Banks) Annual Meeting.
  • "Constantly moving the research field forward is imperative for improving reproductive health services," said Kate Brown, Ph.D., Senior Director of Science at Generate.
  • All of our presented studies addressed fundamental questions that are vital for setting up future research."
  • Generate Life Sciences is a global life sciences company helping families setting out to grow and protect their future, through guidance anchored in scientific advancements and services ranging from preconception into adulthood.

Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells

Thursday, October 21, 2021 - 1:00pm

The partnership also includes a cashinvestmentinto Exacisby CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM,whichwill be used to fund operations.

Key Points: 
  • The partnership also includes a cashinvestmentinto Exacisby CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM,whichwill be used to fund operations.
  • CCRM is a recognized leader in iPSC-derived cell therapy development and manufacturing and we are thrilled to have them as a partner.
  • Their confidence in Exacis is evidenced by the accompanying investment, by CCRM Enterprises Holdings Ltd., underscoring the unique value proposition offered by Exacis' differentiated platform and approach to cell therapies.
  • T and NK cells are types of human immune cells that are ableto recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint

Thursday, October 21, 2021 - 12:30pm

The studys primary endpoint is speech perception, a measure of sound clarity and understanding speech.

Key Points: 
  • The studys primary endpoint is speech perception, a measure of sound clarity and understanding speech.
  • The U.S. Food and Drug Administration (FDA), in a recent Type-C meeting with the Company, agreed that speech perception is an acceptable primary efficacy endpoint.
  • A variety of other listening tests, including multiple measures of speech perception and pure tone thresholds, will also be assessed.
  • In two previous clinical studies, the Company observed statistically significant improvements in speech perception scores in individuals with acquired sensorineural hearing loss.

Dutch stem cell biotech Neuroplast appoints TiGenix founder Frank Luyten and Sanquin director Pieter De Geus to its supervisory board

Thursday, October 21, 2021 - 11:15am

Luyten and De Geus bring a wealth of experience in both clinical translation and regulation as well as manufacturing technologies to Neuroplast.

Key Points: 
  • Luyten and De Geus bring a wealth of experience in both clinical translation and regulation as well as manufacturing technologies to Neuroplast.
  • Dr. Pieter de Geus is Managing Director of Sanquin Health Solutions, which is the commercial branch of Sanquin Foundation.
  • Professor Dr. Luyten and Dr. de Geus bring highly valuable experience in many of the facets and challenges Neuroplast faces.
  • With the additions of Luyten and De Geus, the full supervisory board now consists of five people.

Dutch stem cell biotech Neuroplast appoints TiGenix founder Frank Luyten and Sanquin director Pieter De Geus to its supervisory board

Thursday, October 21, 2021 - 11:15am

GELEEN, Netherlands, Oct. 21, 2021 /PRNewswire/ -- Neuroplast, a Dutch clinical stage biotech, focusing on cell-based treatments for primarily inflammation-driven neurological disorders, today announced the appointment of professor emeritus and TiGenix co-founder Dr. Frank Luyten and Dr. Pieter de Geus, Managing Director of Dutch Sanquin Health Solutions, to its supervisory board. Luyten and De Geus bring a wealth of experience in both clinical translation and regulation as well as manufacturing technologies to Neuroplast. Their expertise supports Neuroplast in further developing cell-based treatments to improve and extend the lives of patients with inflammation-driven neurological disorders like Traumatic Spinal Cord Injury.

Key Points: 
  • Luyten and De Geus bring a wealth of experience in both clinical translation and regulation as well as manufacturing technologies to Neuroplast.
  • Dr. Pieter de Geus is Managing Director of Sanquin Health Solutions, which is the commercial branch of Sanquin Foundation.
  • Professor Dr. Luyten and Dr. de Geus bring highly valuable experience in many of the facets and challenges Neuroplast faces.
  • With the additions of Luyten and De Geus, the full supervisory board now consists of five people.